Pfizer, COVID-19 and Health Canada
Pfizer v Moderna COVID vaccine patents battle to go to appeal in UK
Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the Court of Appeal. Pfizer and its German partner BioNTech sued Moderna in London in September 2022,
Updated Pfizer-BioNTech’s COVID-19 vaccine approved by Health Canada
Health Canada approved Pfizer-BioNTech’s updated COVID-19 vaccine on Tuesday, marking its third authorization of vaccine formulations that protect against the most recently circulating variants of the virus.
Pfizer Canada and BioNTech Receive Health Canada Approval of Omicron KP.2 Variant Adapted COVID-19 Vaccine
Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced today that Health Canada has authorized the KP.2 variant adapted COMIRNATY® COVID-19 vaccine for ages 6 months and older. The updated COMIRNATY® vaccine targets the Omicron KP.
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and
Pfizer’s updated COVID-19 vaccine approved by Health Canada
The mRNA vaccine, called Comirnaty, targets the KP.2 subvariant of Omicron, replacing the previous version which targeted the XBB.1.5 Omicron subvariant.
Health Canada approves Pfizer's updated COVID-19 vaccine, manufacturer says
Pfizer Canada says Health Canada has approved its updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus. The Pfizer-BioNTech mRNA vaccine, called Comirnaty,
Pfizer/BioNTech Covid-19 Vaccine Adapted for KP.2 Strain Gets Canada Approval
Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing opportunities, strengthen advisor-client relationships and build investor experiences. Learn More. Back To Top
STAT21h
Pharmalittle: We’re reading about Pfizer pulling a sickle cell pill, Moderna getting scolded, and more
But the court ruled another similar patent was valid and that Pfizer and BioNTech’s Comirnaty vaccine had infringed it, ...
Pfizer Is Rising Past Covid-19
Pfizer Inc. ( PFE, Financial) rose to prominence during the Covid-19 pandemic for its rapid development of a vaccine and ...
Dr Roland denies instilling fear about Pfizer vaccine
SEPANG: Dr Roland Victor, who is charged with making and initiating the transmission of offensive videos about the Covid-19 ...
Is Pfizer Stock Going to $36? 1 Wall Street Analyst Thinks So.
The company's best days as a top pandemic vaccine supplier might be over, but it still has enough potential to be compelling.
Pfizer Stock Rises 7.3% in 3 Months: Should You Invest Now?
PFE's non-COVID drugs and potential contribution from new and newly acquired products have started to drive growth.
The Prince George Citizen2d
Health Canada approves Pfizer-BioNTech's updated COVID-19 vaccine
BioNTech's updated COVID-19 vaccine that protects against one of the most recently circulating variants of the virus. The ...